Preparations Characterized By Special Physical Form Patents (Class 424/400)
  • Patent number: 11911478
    Abstract: Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: February 27, 2024
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Gerard P. McNally, Anurag Pandey, Vipul Dave
  • Patent number: 11872306
    Abstract: The present invention relates to granules of active ingredient with double taste masking, wherein the double taste masking is achieved by a hot-melt compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and of glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and mixtures thereof, and a thermoplastic polymer that is soluble at a pH less than or equal to 5. The invention also relates to the method for producing these granules and to orodispersible tablets containing these coated granules.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 16, 2024
    Assignee: Ethypharm
    Inventors: Catherine Herry, Caroline Ailhas
  • Patent number: 11867699
    Abstract: This invention provides a method for detecting an analyte in a sample, including a step of contacting said analyte with a nanoparticle to facilitate binding thereto, wherein the nanoparticle comprises: (i) a core; (ii) pores extending radially from said core and being defined by spaces between an array of dendritic spikes radiating outwardly from a surface of the core, wherein the pores have an average pore size of between about 10 nm and about 20 nm; (iii) a binding agent for binding the analyte; and (iv) a detection agent immobilized within said pores; to thereby detect said analyte. This invention also provides kits, compositions and products comprising said nanoparticle.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: January 9, 2024
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Chengzhong Yu, Meihua Yu, Chang Lei, Mohammad Kalantari
  • Patent number: 11858044
    Abstract: A system includes a plurality of building trays, a printing station, a powder delivery station, a powder spreading station, a process compaction station and a stage. The printing station prints a mask pattern on each of the plurality of building trays. The powder delivery station applies a dose of powder material on each of the plurality of building trays. The powder spreading station configured to spread the dose of powder material on each of the plurality of building trays. The process compaction station compacts the powder material. The stage concurrently advances the plurality of building trays to each of the stations to concurrently build a single layer on each the plurality of building trays and repeats the advancing to build a plurality of layers on each of the plurality of building trays. A three dimensional object is formed in each of the building trays.
    Type: Grant
    Filed: May 29, 2017
    Date of Patent: January 2, 2024
    Assignee: Stratasys Ltd.
    Inventor: Yehoshua Sheinman
  • Patent number: 11801219
    Abstract: A pouch product comprising a sealable pouch material comprising i) 0 to 10 wt % Cannabis, ii) 0 to 10 wt % nicotine, whereby nicotine is present in the form of iia) tobacco or iib) as nicotine pure and as nicotine salicylic acid salt at a ratio of pure to salt of 0.20-1:1, and up to of one or more 100 wt % of iii) a sweetener, iv) a pH regulator, and v) essential oil as taste agent. The filling material further comprises vi) up to 76 wt % of a filler consisting of vi-1) 42 to 60 wt % microcrystalline cellulose and vi-2) 11 to 22 wt % potato fibers, at a ratio of 2.0-5:1, and vii) 0.1 to 5 wt % of xanthan gum as a wetting agent, whereby the ratio between microcrystalline cellulose, potato fibers and xanthan gum is 1.0-5:1:0.001-0.4.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: October 31, 2023
    Inventor: Evaggelos Schjölin
  • Patent number: 11795342
    Abstract: A method of preparing a biocompatible polymeric coating includes preparing an aqueous polymer solution by contacting and reacting methacrylic acid and at least one methacrylate or phosphorylcholine. The methacrylate or phosphorylcholine may include hydroxyethyl methacrylate, polyethylene glycol monomethacrylate, or methacryloyloxyethyl phosphorylcholine. An aqueous coupling agent solution is prepared and is either applied to the substrate surface or is mixed with the polymer solution to form a coating solution. If the coupling agent solution was first applied to the substrate surface, the polymer solution is then applied to the primed substrate surface. Alternatively if a coating solution was created, the coating solution is applied to the substrate surface. In either event, the polymer solution and coupling agent solution react with the substrate to form the biocompatible polymeric coating on the substrate surface.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 24, 2023
    Assignee: Acuity Polymers, Inc.
    Inventors: James A. Bonafini, Wayne Thomas Ferrar
  • Patent number: 11793742
    Abstract: Disclosed are cosmetic or pharmaceutical composition comprising a UV filter combination of (a) an aqueous dispersion of 5,6,5?,6?-tetraphenyl-3,3?-(1,4-Phenylene)bis(1,2,4-Triazine) corresponding to the formula in particulate form; and (b) the UV filters selected from (b1) Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine; (b2) Butyl Methoxydibenzoylmethane; (b3) Diethylhexyl Butamido Triazone; (b4) Ethylhexyl Triazone; (b5) Diethylamino Hydroxy Benzoyl Hexyl Benzoate; (b6) Ethyhexyl Methoxycinnamate; (b7) Ethylhexyl Salicylate; (b8) Homosalate; (b9) Octocrylene; (b10) Methylene Bis-Benzotriazolyl Tetramethylbutylphenol; (b11) Phenylbenzimidazole Sulfonic Acid; (b12) Titanium Dioxide; (b13) Tris-Biphenyl Triazine; and (b14) (2-{4-[2-(4-Diethylamino-2-hydroxy-benzoyl)-benzoyl]-piperazine-1-carbonyl}-phenyl)-(4-diethylamino-2-hydroxy-phenyl)-methanone; (b15) BBDAPT; Benzoic acid, 4,4?-[[6-[[3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]-1 disiloxanyl]propyl]amino]-1,3,5-triazine-2,4-diyl]diimino]bis-,
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: October 24, 2023
    Assignee: BASF SE
    Inventors: Thomas Ehlis, Julie Grumelard
  • Patent number: 11793864
    Abstract: This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: October 24, 2023
    Assignees: DERMADIS SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: David Deperthes, Christoph Kundig, Alain Hovnanian, Celine Deraison
  • Patent number: 11779538
    Abstract: The invention relates to an emulsion, e.g. in the form of a salve or a cream, with an aqueous phase and an oil phase, containing an NSAID, characterised in that: (a) the NSAID in the aqueous phase is in a concentration range that corresponds to half to a tenth of the standard concentration for these active substances; (b) the weight ratio of the water-to-oil phase in said emulsion is between the values 2.0 and 2.7; and (c) the pH value of the emulsion is not below the value 6.5 and not above 8.5, preferably in the region of between 7.0 and 8.0, particularly for application in the topical treatment of vaginal fungal infections.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: October 10, 2023
    Assignee: ProFem GmbH
    Inventors: Marion Noe, Christian R. Noe
  • Patent number: 11744796
    Abstract: The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely ? carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, pseudoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: September 5, 2023
    Assignee: Alternative Packaging Solutions, LLC
    Inventor: Mario Elmen Tremblay
  • Patent number: 11723975
    Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 15, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lori S. Burton, William Ying, Nils Lonberg, Sudhir Chakravarthi, Pedro Smith
  • Patent number: 11724134
    Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a body wash, an after shower body lotion, a shampoo, a conditioner, a soap, a gel, a hand sanitizer, a cream, a spray, a mouse, a lotion, an ointment, a make-up product, a lip balm, a hair spray product, an arachnid/insect repellent or a medicinal product.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: August 15, 2023
    Assignee: CoLabs International Corporation
    Inventors: Daniel H. Traynor, Laura E. Cohen
  • Patent number: 11707430
    Abstract: A composition comprises: a base oil; an additive comprising a copolymer comprising hydrophobic and hydrophilic units; and a drug. The copolymer may for example have a comb structure in which the hydrophobic units and hydrophilic units are pendant chains on a backbone of the copolymer. The hydrophobic units and hydrophilic units may for example comprise polydimethylsiloxane moieties and ethylene glycol residues respectively. The composition may for example be used as a tamponade or as a component for a tamponade administered to the eye. The invention is useful for solubilising and/or releasing drugs.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: July 25, 2023
    Assignee: THE UNIVERSITY OF LIVERPOOL
    Inventors: Victoria Kearns, Helen Cauldbeck, Steve Rannard, Rachel Williams, Maude Le Hellaye
  • Patent number: 11691937
    Abstract: The present invention relates to the use, in a cosmetic, dermatological or pharmaceutical composition, of at least one compound of formula (I): in which: R2 represents a hydrogen atom or a methyl or ethyl radical; R3 represents a linear C1-C12 alkyl radical, optionally substituted with a hydroxyl group; or a linear C2-C12 alkenyl radical, optionally substituted with a hydroxyl group; as a preserving agent. The invention also relates to certain novel compounds and to the cosmetic, dermatological or pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: July 4, 2023
    Assignee: L'OREAL
    Inventor: Maria Dalko
  • Patent number: 11690910
    Abstract: The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 4, 2023
    Assignee: CureVac SE
    Inventors: Patrick Baumhof, Thomas Kramps, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek
  • Patent number: 11681789
    Abstract: Systems and methods for authenticating and/or routing a digital signal are provided. A system may include a central database configured to store a set of signature brain wave responses as part of a profile of a user. The system may include a transaction device, a sensory device, and an EEG device. When a transaction request is received from the user, the system may be configured to present the user with a sensory prompt, detect a response of the user to the first sensory prompt, compare the response to the signature response in the profile associated with the sensory prompt, and, when the response matches the signature response within a predetermined delta, authenticate and/or route the transaction request.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: June 20, 2023
    Assignee: Bank of America Corporation
    Inventor: Shailendra Singh
  • Patent number: 11672742
    Abstract: In an example, the deodorant includes a solution. The solution includes a diluent and at least one fruit acid (i.e., at least one alpha hydroxy acid). The solution may also include at least one probiotic. In an embodiment, the deodorant may also include at least one applicator that is configured to hold the solution, such as at least one pad. In an embodiment, a method of using the deodorant may include contacting the armpit (e.g., axilla) or another region of the body with the deodorant to control the body odor of the individual.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: June 13, 2023
    Assignee: Surface Deep LLC
    Inventor: Alicia Zalka
  • Patent number: 11666655
    Abstract: The present disclosure relates to a formulation including: a) a dendron of Formula I; b) at least one bio-therapeutic; c) at least one buffer; and d) at least one salt, wherein the bio-therapeutic to dendron molar ratio is in the range of 1:0.5-1:3. The dendron stabilizes the bio-therapeutic in the formulation at a temperature of up to 55° C.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 6, 2023
    Assignee: Indian Institute of Technology, Delhi
    Inventors: Anurag Singh Rathore, V. Haridas, Rohit Bansal, Soumili Chattopadhyay, Sameer Dhawan
  • Patent number: 11649415
    Abstract: The present invention relates to a composition comprising a) at least one oil phase, b) at least one aqueous phase, c) at-least one emulsifier, wherein the at-least one emulsifier is any or combination of at-least one emulsifier agent, water with emulsification properties, oil with emulsification properties, and active ingredient with emulsification properties; and d) optionally, one or more biologically active ingredients. The present invention also relates to use of the composition for personal care, pet care, home care, deodorants, pesticides, moisturizers, disinfectants, cleansers, therapeutic devices, topical supplements and/or nutrition. The present invention also relates to a method for preparing such a composition.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: May 16, 2023
    Inventor: Reza Fatahi
  • Patent number: 11648187
    Abstract: A method for applying a cosmetic composition to skin is disclosed. The method can include applying a first composition to skin that includes at least about 50% by weight of a volatile hydrocarbon, a film former, a solvent comprising an ester group, and a combination of ultraviolet A (UVA) and ultraviolet B (UVB) sunscreen agents, wherein the UVA sunscreen agent comprises 4-tert-butyl-4?-methoxydibenzoylmethane, wherein the first composition has an SPF of at least about 15 and a PFA of at least about 5, and wherein the first composition dries within two minutes after topical application to skin, and subsequently applying the cosmetic composition onto the first composition.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 16, 2023
    Assignee: MARY KAY INC.
    Inventor: Bob Foley
  • Patent number: 11642292
    Abstract: An aqueous cosmetic includes water, a polyhydric alcohol and carminic acid. A content of the carminic acid is greater than or equal to 0.2 mass % and less than 2 mass % based on a total amount of the aqueous cosmetic.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: May 9, 2023
    Inventor: Shunpei Takezawa
  • Patent number: 11642405
    Abstract: The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: May 9, 2023
    Assignees: Washington University, BLUEWILLOW BIOLOGICS
    Inventors: Shabaana Abdul Khader, Mushtaq Ahmed, Ali Fattom, Douglas Smith, Tarek Hamouda
  • Patent number: 11633520
    Abstract: A tissue graft for soft tissue repair or reconstruction comprising a sheet of a biopolymer-based matrix having a plurality of small perforations and a plurality of large perforations. The small perforations are sized to facilitate clotting and granulation tissue development within the perforations which, in turn, facilitates revascularization and cell repopulation in the patient. The large perforations are sized to reduce the occurrence of clotting and granulation tissue development within the perforations so that extravascular tissue fluids accumulating at the implant site can drain through the tissue graft. The large perforations enhance mammal tissue anchoring by permitting mammal tissue to compress into the perforations increasing mammal tissue contact area.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: April 25, 2023
    Assignee: TEI BIOSCIENCES, INC.
    Inventors: Kevin Cornwell, Kenneth James
  • Patent number: 11590157
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: February 28, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
  • Patent number: 11583819
    Abstract: Nano- to microscale liquid coacervate particles are provided. The liquid coacervate particles are produced by a process including stimulating a population of liquid droplets containing one or a mixture of components to induce a phase separation point of a first component, and maintaining stimulation at the phase separation point to form a coacervate domain of the first component within each of the droplets to form the liquid coacervate particles. The self-assembled nano, meso, micro and macro liquid coacervate particles and related coated substrates can have utility in drug delivery, bioanalytical systems, controlled cell culture, tissue engineering, biomanufacturing and drug discovery.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: February 21, 2023
    Assignees: UNM Rainforest Innovations, Duke University
    Inventors: Gabriel P. Lopez, Joseph R. Simon, Nick J. Carroll, Ashutosh Chilkoti
  • Patent number: 11576905
    Abstract: The invention provides topical pharmaceutical gel compositions for the treatment of chronic skin damage, specifically for damage caused by neuropathic ulcers and preferably for the treatment of diabetic foot, and in the treatment of vascular ulcers wherein said compositions comprise a combination of Modified Diallyl Disulfide Oxide (M-DDO) (as an antiseptic/antibiotic agent) and 5-methyl-1-phenyl-2(1H)-pyridone. Furthermore, the invention describes methods of treatment, applications and/or pharmaceutical uses in the preparation of medicaments for eliminating, reducing or preventing chronic skin lesions and the damages caused by neuropathic ulcers and particularly in the treatment of diabetic foot and in the treatment of vascular ulcers.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: February 14, 2023
    Assignee: Excalibur Pharmaceuticals, Inc.
    Inventors: José Agustín Rogelio Magaña Castro, Juan Socorro Armendáriz Borunda
  • Patent number: 11572341
    Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 7, 2023
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo Kim, Jae Kap Jeong, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Sung Wuk Kim
  • Patent number: 11559523
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: January 24, 2023
    Assignee: Helsinn Healthcare SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Patent number: 11547116
    Abstract: Described is an initial liquid composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising chelated metal oxide particles suspended in a polyol, such that metal oxide particles are homogeneously dispersed in a primarily liquid based polyol carrier so that chelated metal oxide particles form a stable complex suspension that is optionally an alkaline based aqueous silver oxide dispersion. The liquid composition can be subsequently added to any polymer or polymer compound/system where the polymer degrades or melts at a temperature lower than the polyol carrier degradation or boiling temperature. The metal oxide complex may also impart beneficial semi-conductive or conductive as well as permeability and flammability property changes to the polymer (host) system.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: January 10, 2023
    Inventors: William Wingfield, Guerry L Grune, Richard L Mason
  • Patent number: 11541002
    Abstract: An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 3, 2023
    Assignee: Aquestive Therapeutics, Inc.
    Inventors: Alexander Mark Schobel, Stephen Wargacki, Vincent J. Buono, Susan Shumard, Christopher James Santee
  • Patent number: 11534405
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: December 27, 2022
    Assignee: CureVac AG
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Patent number: 11529369
    Abstract: Described herein are methods for modulating expression of a gene in a cell by contacting the cell with a gene modulation composition, such as a composition including an electrolyzed saline solution.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 20, 2022
    Assignee: RDG HOLDINGS, INC.
    Inventor: Kurt Richards
  • Patent number: 11529301
    Abstract: A composition and methods for lubricating mucous membranes including reproductive tissue with a topical lubricant and at least one cannabinoid. Cannabis and cannabinoids are solubilized and combined with water-based personal lubricants.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: December 20, 2022
    Assignee: Resurgent Biosciences, Inc.
    Inventors: Eric Greenbaum, Justin Bueno, Emily Leuer, Kyle Kingsley
  • Patent number: 11529360
    Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: December 20, 2022
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio, Frederick D. Sancilio
  • Patent number: 11512042
    Abstract: The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy and having improved properties.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: November 29, 2022
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Mark York, John Ryan
  • Patent number: 11491086
    Abstract: The present disclosure relates to delivery systems. More particularly, the present disclosure relates to a process for releasing an active ingredient including a step of contacting a powdered composition with a medium having a pH?7. The powdered composition includes granules made of a water soluble polymer matrix, an oil phase dispersed in said matrix and carbonate particles. Consumer products such as an antiperspirant or deodorant composition or a powder soft drink beverage composition including the powdered composition are also object of the present disclosure.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: November 8, 2022
    Assignee: FIRMENICH SA
    Inventors: Pierre-Etienne Bouquerand, Pascal Beaussoubre, Wolfgang Fieber, François Meyer
  • Patent number: 11478574
    Abstract: The present disclosure provides an engineered collagen composition comprising collagen, wherein the collagen composition is compressed to form a gradient of at least one physical property. Methods of using and of manufacturing the engineered collagen compositions of the present disclosure are also provided.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 25, 2022
    Assignee: Purdue Research Foundation
    Inventors: Sherry L. Voytik-Harbin, Tyler Anthony Novak, Kevin Blum, Corey Philip Neu
  • Patent number: 11471791
    Abstract: A process is provided for separating hydrophobic material from a mixture of hydrophobic and hydrophilic material using peptide-based amphiphilic organogelators.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: October 18, 2022
    Assignee: Hindustan Petroleum Corporation Limited
    Inventors: Raman Ravishankar, Chinthalapati Sivakesava Raju, Jitalaxmi Bharali, Sheshachala Srinivasa Narasimha, Peddy Venkat Chalapathi Rao, Nettem Venkateswarlu Choudary
  • Patent number: 11452687
    Abstract: Oral medicament comprising an osmotic laxative incorporated into a matrix based on plant fats. The present invention relates to an oral pharmaceutical composition comprising: between 30 and 55% by weight of said pharmaceutical composition of micronized anhydrous macrogol; and between 45 and 70% by weight of the pharmaceutical composition of a carrier consisting of an anhydrous hydrophobic lipid coating based on fatty compounds of plant origin, having a melting point of between 36 and 38° C., and to the use thereof as laxative. Said composition enables the reduction in the daily dosage of macrogol by preserving the osmotic pressure thereof as far as the colon, the site of therapeutic action of osmotic laxatives; said carrier protects the macrogol from a reduction, due to the moisture in the digestive tract, in the osmotic pressure.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 27, 2022
    Assignee: SALSARULO PHARMA
    Inventors: Gérard Salsarulo, Gilles Salsarulo
  • Patent number: 11452742
    Abstract: The present disclosure relates to pharmaceutical compositions comprising zinc, copper, at least one micronutrient, and a pharmaceutically acceptable excipient; and comprising administering, to a subject in need thereof, a pharmaceutical composition comprising zinc, copper, at least one micronutrient, and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: September 27, 2022
    Assignees: ZINCUM, INC., WAYNE STATE UNIVERSITY
    Inventors: Ananda S. Prasad, Roy A. Varghese, Kenneth W. Brown, Richard P. Scheckenbach
  • Patent number: 11446243
    Abstract: The present disclosure provides an oral liquid composition comprising valsartan with enhanced solubility and stability. Also, provided herein are methods of using the oral liquid compositions for the treatment of hypertension, treatment of heart failure and reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.
    Type: Grant
    Filed: July 3, 2020
    Date of Patent: September 20, 2022
    Assignee: ECI PHARMACEUTICALS, LLC
    Inventor: Nirali R. Bhatt
  • Patent number: 11446412
    Abstract: Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: September 20, 2022
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Lola M. Reid, Wencheng Zhang, Eliane Wauthier
  • Patent number: 11446257
    Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: September 20, 2022
    Assignees: BioPhysics Pharma, Inc.
    Inventors: John J. Masiz, Zhen Zhu
  • Patent number: 11446259
    Abstract: Provided herein are water soluble solid form compositions including a curcuminoid; and a solubilizer selected from one or more of methylsulfonylmethane (MSM) and steviol glycoside; glycerol polyethylene glycol hydroxystearate (GPGH) and steviol glycoside; fatty acid glycerol polyglycoester (GPE); steviol glycoside and an aromatic amino acid; and steviol glycoside. Also provided herein are methods of making the water soluble solid form compositions.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: September 20, 2022
    Assignee: InovoBiologic Inc.
    Inventors: Chuck Chang, Sangho Lee, Youngse Jang, Yoon Seok Roh
  • Patent number: 11446240
    Abstract: The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely ? carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, psuedoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: September 20, 2022
    Inventor: Mario Elmen Tremblay
  • Patent number: 11433090
    Abstract: The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-? (TGF-?) signal and/or extracellular matrix (ECM).
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: September 6, 2022
    Assignee: The Doshisha
    Inventors: Noriko Koizumi, Naoki Okumura
  • Patent number: 11433027
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: September 6, 2022
    Assignee: CureVac AG
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Patent number: 11426457
    Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell C1 epitopes, wherein the peptide is attached to a nanoparticle.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 30, 2022
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • Patent number: 11419866
    Abstract: The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: August 23, 2022
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, MingHsin Li, Chen-Chang Lee, Chia-Ying Yang, Chih-Ying Lin
  • Patent number: 11419835
    Abstract: Described herein are methods of reducing the risk of recurrence of bacterial vaginosis by intravaginal administration of compositions comprising L-lactic acid, polymer thickener, and preservative.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: August 23, 2022
    Assignee: Evofem, Inc.
    Inventor: David R. Friend